{"id":"sublingual-buprenorphine-naloxone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Buprenorphine's partial agonism provides analgesia with a ceiling effect, reducing the risk of overdose and dependence. Naloxone's antagonism helps to prevent misuse and overdose by blocking the effects of opioids.","oneSentence":"Buprenorphine is a partial opioid agonist that binds to opioid receptors, while naloxone is an opioid antagonist that blocks opioid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:35.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of opioid use disorder"}]},"trialDetails":[{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT04948307","phase":"NA","title":"OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2021-06-30","conditions":"Opioid-use Disorder","enrollment":437},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT04447287","phase":"PHASE1","title":"A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-06-29","conditions":"Opioid Use Disorder","enrollment":23},{"nctId":"NCT04737603","phase":"PHASE2","title":"Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2025-07-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT05062577","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-11-08","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT05644587","phase":"PHASE4","title":"Novel Induction to Buprenorphine/Naloxone","status":"TERMINATED","sponsor":"Bicycle Health","startDate":"2023-02-06","conditions":"Opioid Use Disorder, Opioid Use, Opioid Abuse","enrollment":33},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT04716413","phase":"PHASE4","title":"Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-09-27","conditions":"Acute Pain","enrollment":3},{"nctId":"NCT04991974","phase":"PHASE2, PHASE3","title":"Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine","status":"UNKNOWN","sponsor":"Friends Research Institute, Inc.","startDate":"2021-09-17","conditions":"Opioid-use Disorder","enrollment":360},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT03818399","phase":"PHASE3","title":"Virginia Opioid Overdose Treatment InitiatVE","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2019-01-04","conditions":"Opioid Use Disorder","enrollment":19},{"nctId":"NCT03492099","phase":"PHASE2","title":"Assessing the Safety of Buprenorphine in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-01","conditions":"Sickle Cell Disease","enrollment":47},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT03248947","phase":"EARLY_PHASE1","title":"Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-03-28","conditions":"Opioid Use Disorder","enrollment":71},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT03033732","phase":"PHASE4","title":"A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse","status":"COMPLETED","sponsor":"Didier Jutras Aswad","startDate":"2017-10-02","conditions":"Opioid Use Disorder","enrollment":272},{"nctId":"NCT04523792","phase":"PHASE3","title":"Virginia Opioid Treatment-Emergency Department","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2021-01-01","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03015246","phase":"PHASE1, PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":"Heroin Dependence, Opioid Use Disorder","enrollment":26},{"nctId":"NCT04212065","phase":"PHASE4","title":"Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2020-02-21","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT04088266","phase":"PHASE4","title":"An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.","status":"WITHDRAWN","sponsor":"Teva Pharmaceuticals USA","startDate":"2020-01","conditions":"Evaluation of QTc Interval","enrollment":""},{"nctId":"NCT01550341","phase":"NA","title":"HIV, Buprenorphine, and the Criminal Justice System","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-02-23","conditions":"Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction","enrollment":50},{"nctId":"NCT03766893","phase":"EARLY_PHASE1","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"COMPLETED","sponsor":"Lifespan","startDate":"2018-09-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT03420313","phase":"PHASE2","title":"Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2018-03-01","conditions":"Opioid-use Disorder","enrollment":100},{"nctId":"NCT01967641","phase":"PHASE2","title":"Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-11","conditions":"Opioid Dependence","enrollment":51},{"nctId":"NCT02180659","phase":"PHASE3","title":"A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants","status":"COMPLETED","sponsor":"Titan Pharmaceuticals","startDate":"2014-07","conditions":"Opioid Dependence","enrollment":177},{"nctId":"NCT01262261","phase":"PHASE3","title":"Re-Treatment Study of Probuphine in Opioid Addiction","status":"COMPLETED","sponsor":"Titan Pharmaceuticals","startDate":"2010-11","conditions":"Opioid Dependency","enrollment":85},{"nctId":"NCT00768482","phase":"PHASE3","title":"A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2008-09","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT01114308","phase":"PHASE3","title":"A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction","status":"COMPLETED","sponsor":"Titan Pharmaceuticals","startDate":"2010-04","conditions":"Opioid Dependency","enrollment":287},{"nctId":"NCT03489161","phase":"EARLY_PHASE1","title":"Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2018-08-01","conditions":"Drug Overdose, Opioid Withdrawal, Opioid-use Disorder","enrollment":3},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT01841931","phase":"NA","title":"Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients","status":"TERMINATED","sponsor":"Maimonides Medical Center","startDate":"2013-02","conditions":"Opioid Use Disorder","enrollment":4},{"nctId":"NCT02510014","phase":"PHASE3","title":"Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-07-27","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":775},{"nctId":"NCT01407575","phase":"PHASE3","title":"Buprenorphine for Treatment Resistant Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-09","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":13},{"nctId":"NCT02357901","phase":"PHASE3","title":"Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-01-28","conditions":"Opioid Dependence, Opioid Related Disorders","enrollment":665},{"nctId":"NCT02243670","phase":"NA","title":"Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy","status":"COMPLETED","sponsor":"AiCure","startDate":"2016-08","conditions":"Opiate Addiction, Medication Non-adherence, Addiction","enrollment":9},{"nctId":"NCT01188421","phase":"PHASE1, PHASE2","title":"Medications Development for Drug Abuse Disorders","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-10","conditions":"Opioid Related Disorders, Opioid Dependence, Opioid Addiction","enrollment":106},{"nctId":"NCT00604188","phase":"PHASE4","title":"A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-22","conditions":"Opiate Dependence, Drug Dependence, Substance Dependence","enrollment":188},{"nctId":"NCT01260675","phase":"","title":"Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone","status":"COMPLETED","sponsor":"NanoSHIFT LLC","startDate":"2010-12","conditions":"Healthy","enrollment":12},{"nctId":"NCT01848054","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-06","conditions":"Opioid-Related Disorders, Opiate Dependence","enrollment":313},{"nctId":"NCT01908842","phase":"PHASE3","title":"Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-08","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":759},{"nctId":"NCT01396005","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Hepatitis C Virus","enrollment":21},{"nctId":"NCT02038790","phase":"PHASE4","title":"Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Dependence","enrollment":33},{"nctId":"NCT00725608","phase":"","title":"Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-05","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":339},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47},{"nctId":"NCT01582347","phase":"PHASE2","title":"Transfer of Subjects From Subutex/Suboxone to RBP-6300","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-03","conditions":"Opioid Related Disorder","enrollment":143},{"nctId":"NCT00000320","phase":"PHASE1, PHASE2","title":"Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1997-10","conditions":"Opioid-Related Disorders","enrollment":120},{"nctId":"NCT00134914","phase":"NA","title":"Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-08","conditions":"Opioid-Related Disorders","enrollment":10},{"nctId":"NCT00134875","phase":"NA","title":"Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-12","conditions":"Opioid-Related Disorders","enrollment":9},{"nctId":"NCT00733720","phase":"PHASE1","title":"Buprenorphine Naltrexone-P1 A-Cocaine","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2008-08","conditions":"Cocaine-related Disorders","enrollment":8},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT01846455","phase":"PHASE4","title":"Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-09","conditions":"Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma","enrollment":43},{"nctId":"NCT00605033","phase":"PHASE4","title":"A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-03","conditions":"Opiate Dependence, Drug Dependence","enrollment":241},{"nctId":"NCT02249026","phase":"PHASE1, PHASE2","title":"Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study","status":"UNKNOWN","sponsor":"Gauda, Estelle B., M.D.","startDate":"2014-10","conditions":"Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication","enrollment":40},{"nctId":"NCT01903005","phase":"PHASE4","title":"Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2013-07","conditions":"Opioid Dependence, on Agonist Therapy","enrollment":668},{"nctId":"NCT02477267","phase":"PHASE1","title":"Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2015-06","conditions":"Opiate Dependence","enrollment":47},{"nctId":"NCT01052662","phase":"PHASE2, PHASE3","title":"Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-10","conditions":"Opioid Dependence","enrollment":87},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01015066","phase":"PHASE4","title":"Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents","status":"WITHDRAWN","sponsor":"State University of New York at Buffalo","startDate":"2009-11","conditions":"Opiate Addiction","enrollment":""},{"nctId":"NCT00955162","phase":"PHASE4","title":"Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (\"RIME\")","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2009-08","conditions":"Opioid Dependency","enrollment":270},{"nctId":"NCT00901875","phase":"PHASE4","title":"Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2009-03","conditions":"Opiate Dependence","enrollment":127},{"nctId":"NCT00640835","phase":"PHASE2","title":"Safety and Tolerability of Buprenorphine/Naloxone Film Strips","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-02","conditions":"Opioid-Related Disorders","enrollment":382},{"nctId":"NCT00723749","phase":"","title":"Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2008-03","conditions":"Opioid-Related Disorders, Opiate Dependence, Drug Abuse","enrollment":384},{"nctId":"NCT01275599","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Telaprevir and Buprenorphine","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-01","conditions":"Hepatitis C, Opioid-Related Disorders","enrollment":16},{"nctId":"NCT00552578","phase":"PHASE4","title":"Buprenorphine as a Treatment in Opiate Dependent Pain Patients","status":"TERMINATED","sponsor":"State University of New York at Buffalo","startDate":"2007-10","conditions":"Opiate Addiction, Refractory Pain","enrollment":12},{"nctId":"NCT00612287","phase":"PHASE2","title":"Sublingual Buprenorphine for Chronic Pain","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2009-04","conditions":"Chronic Pain","enrollment":40},{"nctId":"NCT00007527","phase":"PHASE4","title":"Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1999-08","conditions":"Opiate Dependence","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SL-BUP"],"phase":"phase_3","status":"active","brandName":"Sublingual buprenorphine-naloxone","genericName":"Sublingual buprenorphine-naloxone","companyName":"Yih-Ing Hser","companyId":"yih-ing-hser","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial opioid agonist that binds to opioid receptors, while naloxone is an opioid antagonist that blocks opioid receptors. Used for Treatment of opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}